Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Total Debt (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Total Debt for 16 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Debt fell 42.75% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Sep 2025, down 42.75%, and an annual FY2024 reading of $2.5 million, changed 0.38% over the prior year.
  • Total Debt was $1.4 million for Q3 2025 at China Pharma Holdings, down from $2.7 million in the prior quarter.
  • Across five years, Total Debt topped out at $4.6 million in Q3 2022 and bottomed at $1.4 million in Q3 2025.
  • Average Total Debt over 5 years is $3.0 million, with a median of $2.7 million recorded in 2025.
  • The sharpest move saw Total Debt surged 86.18% in 2021, then plummeted 47.58% in 2023.
  • Year by year, Total Debt stood at $4.3 million in 2021, then plummeted by 43.61% to $2.4 million in 2022, then increased by 4.29% to $2.5 million in 2023, then decreased by 0.38% to $2.5 million in 2024, then crashed by 44.27% to $1.4 million in 2025.
  • Business Quant data shows Total Debt for CPHI at $1.4 million in Q3 2025, $2.7 million in Q2 2025, and $2.5 million in Q1 2025.